According to the gene expression, patients were categorized into two subgroups, and the patients with a higher SLC11A1 expression had a lower rate of IDH mutation and higher rates of EGFR and PTEN mutations (Figures 3E, F and Supplementary Figure 1A), and which are considered to indicate a poor prognosis for glioma patients. The gene discussed is SLC11A1; the disease is central nervous system cancer.